S. 891 is a comprehensive health care bill introduced in March 2025 that addresses Medicaid and Medicare reforms, prescription drug pricing transparency, pandemic preparedness, and public health initiatives. The legislation makes significant changes to pharmacy benefit manager oversight—requiring detailed reporting on drug costs and rebates to health plans and establishing transparent pricing models for Medicaid—while extending Medicare payment programs and telehealth flexibilities through 2026-2027. The bill also expands home and community-based services for Medicaid beneficiaries, increases funding for opioid treatment and recovery programs, enhances disaster preparedness with new biocontainment laboratories and disease surveillance systems, and establishes new maternal health and pediatric drug research initiatives. Key appropriations include $71 million for home and community-based services demonstrations, $113 million to CMS for pharmacy benefit manager oversight, $1.1–1.21 billion for pandemic medical countermeasures, and $950 million for pandemic-threat research through fiscal year 2026, with most provisions taking effect in 2025–2029.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.